October 13, 2015 / 12:35 PM / 2 years ago

BUZZ-Aeterna Zentaris Inc: Committee recommends late-stage trial continue

1 Min Read

** Canadian drug developer's U.S.-listed shares up 15 pct at 9 cents

** Aeterna says an independent data and safety monitoring committee recommended it continue testing its endometrial cancer drug in a late-stage study

** The drug, zoptarelin doxorubicin, is being tested in women with advanced, recurrent or metastatic endometrial cancer; drug is also being evaluated for use in ovarian and prostate cancer

** If all goes well, the drug could become the first FDA-approved therapy for the condition, company says

** There will be about 50,000 new cases of endometrial cancer in the U.S. in 2015, about 20 pct of which will recur, the American Cancer Society estimates

** Up to Monday's close, U.S.-listed stock had risen about 87 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below